Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial-Reference-Cited by-同舟云学术

Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial

Published:2019-12 Issue:4 Volume:1 Page:e208-e219
ISSN:2665-9913
Container-title:The Lancet Rheumatology
language:en
Short-container-title:The Lancet Rheumatology

Author:

Furie Richard A,Morand Eric F,Bruce Ian N,Manzi Susan,Kalunian Kenneth C,Vital Edward M,Lawrence Ford Theresa,Gupta Ramesh,Hiepe Falk,Santiago Mittermayer,Brohawn Philip Z,Berglind Anna,Tummala Raj

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference40 articles.

1. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort;Bruce;Ann Rheum Dis,2015

2. Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999–2014);Jorge;Rheumatology,2018

3. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus;Furie;Arthritis Rheum,2011

4. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial;Navarra;Lancet,2011

5. Lupus in crisis: as failures pile up, clinicians call for new tools;Dolgin;Nat Biotechnol,2019

Cited by 318 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic glucocorticoid therapy for SLE;Dubois' Lupus Erythematosus and Related Syndromes;2025

2. Future directions;Dubois' Lupus Erythematosus and Related Syndromes;2025

3. Targeted therapies in SLE;Dubois' Lupus Erythematosus and Related Syndromes;2025

4. Clinical markers, metrics, indices, and clinical trials;Dubois' Lupus Erythematosus and Related Syndromes;2025

5. Cytokines in lupus;Dubois' Lupus Erythematosus and Related Syndromes;2025